Telomir Pharmaceuticals (TELO) Accumulated Expenses (2025)
Telomir Pharmaceuticals (TELO) posted Accumulated Expenses of $417470.0 for Q4 2025.
Telomir Pharmaceuticals (TELO) Accumulated Expenses (2025) Analysis & Trends
Telomir Pharmaceuticals has reported Accumulated Expenses for 1 years, with the latest figure at $417470.0 in Q4 2025.
- Quarterly Accumulated Expenses changed N/A year-over-year to $417470.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $417470.0 (changed N/A YoY) and the FY2025 annual result came in at $417470.0, changed N/A from the prior year.
- Accumulated Expenses was little changed at $417470.0 in Q4 2025 per TELO's latest filing.
- Over five years, Accumulated Expenses peaked at $417470.0 in Q4 2025 and troughed at $417470.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Telomir Pharmaceuticals | 69.05 Mn | 69.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 417,470.00 |